Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) shares were down 2.1% during trading on Friday following insider selling activity. The company traded as low as $271.37 and last traded at $271.37. Approximately 116,912 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 879,838 shares. The stock had previously closed at $277.33.
Specifically, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Analysts Set New Price Targets
A number of research firms have weighed in on ALNY. TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Evercore ISI boosted their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 25th. Chardan Capital restated a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. UBS Group lifted their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Finally, JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research note on Wednesday, July 3rd. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $277.14.
Alnylam Pharmaceuticals Stock Performance
The company has a market cap of $34.49 billion, a P/E ratio of -102.79 and a beta of 0.37. The stock has a 50-day simple moving average of $241.88 and a 200 day simple moving average of $183.12.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The firm’s revenue was up 107.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.21) earnings per share. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 4,809 shares in the last quarter. Westpac Banking Corp increased its position in Alnylam Pharmaceuticals by 59.8% in the 4th quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.